keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/28617374/-positive-changes-in-the-severity-of-residual-psychotic-symptoms-in-schizophrenic-patients-switched-to-treatment-with-risperidone
#1
D S Burminskiy, M A Morozova
AIM: To evaluate the effect of changing therapy from typical antipsychotics to the atypical antipsychotic risperidone in the treatment of difficult-to-treat residual psychotic symptoms. MATERIAL AND METHODS: The study included 15 patients, 8 men and 7 women, mean age 49.1±10.25 years, diagnosed with paranoid schizophrenia, partial remission (ICD-10 F20.04). At the beginning all participants received regular maintenance antipsychotic therapy with typical antipsychotics...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28612649/a-brain-on-a-roller-coaster-can-the-dopamine-reward-system-act-as-a-protagonist-to-subdue-the-ups-and-downs-of-bipolar-disorder
#2
Shokouh Arjmand, Mina Behzadi, Gary J Stephens, Sara Ezzatabadipour, Rostam Seifaddini, Shahrad Arjmand, Mohammad Shabani
One of the most interesting but tenebrous parts of the bipolar disorder (BD) story is the switch between (hypo)mania and depression, which can give bipolar patients a thrilling, but somewhat perilous, 'ride'. Numerous studies have pointed out that there are some recognizable differences (either state-dependent or state-independent) in several brain regions of people with BD, including components of the brain's reward system. Understanding the underpinning mechanisms of high and low mood statuses in BD has potential, not only for the development of highly specific and selective pharmaceutical agents, but also for better treatment approaches and psychological interventions to manage BD and, thus, give patients a safer ride...
June 1, 2017: Neuroscientist: a Review Journal Bringing Neurobiology, Neurology and Psychiatry
https://www.readbyqxmd.com/read/28596830/the-effect-of-switching-from-oral-low-dose-aripiprazole-to-aripiprazole-once-monthly-300-mg-on-the-quality-of-life-in-three-patients-with-schizophrenia
#3
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami
BACKGROUND: Schizophrenia is a chronic disease that requires long-term management with antipsychotics; however, an important barrier to the success of long-term treatment is drug noncompliance, which increases the risk of recurrence and hospitalization. Second-generation long-acting injectable antipsychotics have improved drug adherence, and the pharmacological effects of the drugs, and therefore, have become useful treatment options. METHODS: We report on three schizophrenia patients who switched from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28593216/real-world-effectiveness-of-antipsychotic-treatments-in-a-nationwide-cohort-of-29%C3%A2-823-patients-with-schizophrenia
#4
Jari Tiihonen, Ellenor Mittendorfer-Rutz, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Heidi Taipale
Importance: It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing to the impossibility of including large unselected patient populations in randomized clinical trials, as well as residual confounding from selection biases in observational studies. Objective: To study the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia...
June 7, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28558905/correlates-and-predictors-of-antipsychotic-drug-polypharmacy-in-real-life-settings-results-from-a-nationwide-cohort-study
#5
Leo Malandain, Florence Thibaut, Lamiae Grimaldi-Bensouda, Bruno Falissard, Lucien Abenhaim, Clementine Nordon
Reasons for using antipsychotic polypharmacy (APP) in routine clinical practice, despite a potentially unfavorable risk-benefit ratio, are poorly understood. This research aimed to determine (1) if severe courses of schizophrenia were associated with APP and (2) if a schizophrenia-related acute event would predict a switch to APP in the short term. Observational prospective data (at baseline and 6months) were drawn from a French nationwide cohort ("Cohorte Générale Schizophrénie"), which included 1859 inpatients and outpatients with schizophrenia...
May 27, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28552242/-switching-from-antipsychotics-to-aripiprazole-and-risk-of-agitation
#6
B Chaumette, M Masson, M Barde, O Gay, R Gaillard
The exact modalities of switching between two antipsychotics are rarely studied despite the high frequency of this issue in clinical practice. In this context, description of clinical cases may be enlightening. We report on three new cases of agitation after replacing a dopaminergic antagonist with aripiprazole. A literature review indicated no other predictive clinical feature associated with a higher risk of agitation than therapeutic history. In fact, patients who previously received a greater dose of antipsychotic are more at risk to present paradoxical agitation when switching to aripiprazole...
May 25, 2017: L'Encéphale
https://www.readbyqxmd.com/read/28542034/dopamine-d2-receptor-affinity-of-antipsychotics-in-relation-to-subjective-well-being-in-patients-with-a-psychotic-disorder
#7
Iris E de Wit, Floor A van Dijk, Carin J Meijer, Mirjam J van Tricht, Lieuwe de Haan
Dopamine D2-receptor blockade by antipsychotic medication reduces psychotic symptoms, but may reduce subjective well-being. The current study aims to further explore the relation between dopamine D2-receptor affinity and subjective well-being within a large sample of patients with psychotic disorders. Patients participated in a longitudinal naturalistic cohort study: the Genetic Risk and Outcome of Psychosis (GROUP) study. Three groups of antipsychotic medication were created on the basis of their affinity for the D2-receptor: (i) loose or partial agonistic binding, (ii) moderate binding, and (iii) tight binding...
May 24, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28540050/effect-of-atypical-antipsychotics-on-body-weight-in-geriatric-psychiatric-inpatients
#8
Eugene Yh Yeung, Soojin Chun, Alan Douglass, Timothy E Lau
BACKGROUND: Studies suggest that antipsychotic-induced weight gain is not a great concern in the elderly population. This study investigated the weight change in elderly patients with various treatment duration and antipsychotics. Part 1 of the study was to determine whether atypical antipsychotics induced weight change in elderly patients. Part 2 was to determine whether certain atypical antipsychotics induced more weight change in elderly patients. METHODS: In Part 1, a retrospective chart review was done on 115 geriatric inpatients...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28539959/tardive-dystonia-related-with-aripiprazole
#9
Sunghwan Kim, Seung-Yup Lee, MinSeob Kim, Kyoung-Uk Lee
Tardive dystonia is characterized by sustained, generally slow involuntary twisting movements. It is estimated to occur at a frequency of 1% to 4% among patients who are taking an antipsychotic agent. Unlike the first generation antipsychotics, the second generation antipsychotics are less likely to cause neuroleptic-induced movement disorder. For aripiprazole, only a few cases have been reported for tardive dystonia. We present a young male, who developed a severe tardive dystonia after taking aripiprazole for 5 years...
May 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28522434/one-year-symptom-trajectories-in-patients-with-stable-schizophrenia-maintained-on-antipsychotics-versus-placebo-meta-analysis
#10
REVIEW
Hiroyoshi Takeuchi, Navot Kantor, Marcos Sanches, Gagan Fervaha, Ofer Agid, Gary Remington
BackgroundAs definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome.AimsTo compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia.MethodRandomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included...
May 18, 2017: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/28503156/effects-of-antipsychotic-administration-on-brain-glutamate-in-schizophrenia-a-systematic-review-of-longitudinal-1-h-mrs-studies
#11
REVIEW
Alice Egerton, Akarmi Bhachu, Kate Merritt, Grant McQueen, Agata Szulc, Philip McGuire
Schizophrenia is associated with brain glutamate dysfunction, but it is currently unclear whether antipsychotic administration can reduce the extent of glutamatergic abnormality. We conducted a systematic review of proton magnetic resonance spectroscopy ((1)H-MRS) studies examining the effects of antipsychotic treatment on brain glutamate levels in schizophrenia. The Medline database was searched to identify relevant articles published until December 2016. Inclusion required that studies examined longitudinal changes in brain glutamate metabolites in patients with schizophrenia before and after initiation of first antipsychotic treatment or a switch in antipsychotic treatment...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28492458/switching-from-the-oral-to-the-depot-formulation-of-a-medication-clinically-relevant-pharmacokinetic-concepts-and-considerations
#12
Sheldon H Preskorn
This column presents principles that will aid the prescriber in transitioning patients from an oral to a depot antipsychotic medication. The column covers the differences in the pharmacokinetics of oral versus depot formulations that are critical in making a smooth transition. Also discussed are some of the reasons to use these medications, which, in the author's opinion, are currently underutilized. This column focuses on the big picture and the fundamentals of oral versus depot formulations rather than comparing the relative merits or potential advantages of the various marketed depot formulations...
May 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28464773/the-role-of-atypical-antipsychotics-in-sexuality-road-to-recovery-in-schizophrenia
#13
Raja Lope Adam, Hatta Sidi, Marhani Midin, Hazli Zakaria, Srijit Das, Khairi Che Mat
Sexuality is an important dimension in human beings as a form of expression of individuality. For many decades, sexual functioning has been a neglected area among patients suffering from schizophrenia. It was a presumption that patients with schizophrenia could be asexual and this could be secondary to overwhelming situations of delusion, hallucination, hostility and negative symptoms among others. The deficient in sexual functioning are due to innate factors, i.e. negative symptoms (apathy, avolition and amotivation) and also as a result of prefrontal dysfunction, i...
May 2, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28461752/the-effectiveness-and-safety-of-amisulpride-in-chinese-patients-with-schizophrenia-who-switch-from-risperidone-or-olanzapine-a-subgroup-analysis-of-the-escape-study
#14
Ying Liang, Xin Yu
INTRODUCTION: Second-generation antipsychotics show significant interpatient variability in treatment response and side-effect profiles, and the majority of patients with schizophrenia require multiple treatment changes. This subgroup analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in Chinese patients with schizophrenia who switched from risperidone or olanzapine. METHODS: ESCAPE was a prospective, open-label, multicenter, single-arm Phase IV study in which Chinese patients with an ICD-10 diagnosis of schizophrenia received amisulpride for 8 weeks...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28458549/treatment-satisfaction-with-paliperidone-extended-release-tablets-open-label-study-in-schizophrenia-patients-dissatisfied-with-previous-antipsychotic-medication
#15
Fu De Yang, Juan Li, Yun Long Tan, Wei Ye Liang, Rongzhen Zhang, Ning Wang, Wei Feng, Shangli Cai, Jian Min Zhuo, Li Li Zhang
OBJECTIVE: The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment. METHODS: In this 8-week, open-label, single-arm, multicenter, prospective study, 1,693 patients dissatisfied with previous antipsychotic medication were enrolled and switched to paliperidone ER tablets (3-12 mg/d) based on clinical judgment...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28346773/noninterventional-naturalistic-retrospective-study-to-describe-prescription-patterns-of-long-acting-injectable-antipsychotics-and-the-impact-of-introducing-a-new-atypical-antipsychotic-in-the-spanish-province-of-tarragona-catchment-area
#16
Ana M Gaviria, José Franco, Guillem Rico, Gerard Muntané, Cristina Sáez, Vanessa Sánchez-Gistau, Joan de Pablo, Elisabet Vilella
Background: We studied the patterns and predictors of long-acting injectable (LAI) antipsychotic (AP) use in the treatment of schizophrenia and the effect of introducing a new LAI (paliperidone palmitate [paliperidone-LAI]) in the Spanish province of Tarragona. Methods: This noninterventional, naturalistic, retrospective study included electronic medical record data from a large population-based database of 1,646 patients who were diagnosed with schizophrenia according to ICD-10 criteria and treated between January 2011 and December 2013...
March 23, 2017: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#17
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28288438/epidemiology-of-pharmaceutically-treated-depression-and-treatment-resistant-depression-in-taiwan
#18
Daniel Fife, Yu Feng, Michael Yao-Hsien Wang, Chee-Jen Chang, Chia-Yih Liu, Hsiao-Ting Juang, Wesley Furnback, Jaskaran Singh, Bruce Wang
Epidemiologic data on treatment resistant depression (TRD) in Asia-Pacific countries are limited. We estimated the incidence of TRD in Taiwan using a cohort of 704,265 adults randomly sampled from Taiwan's National Health Insurance Research database for 2005. TRD was defined as a patient having pharmaceutically treated depression (PTD) not adequately responding to 2 antidepressant (AD) regimens, i.e., AD regimens that were followed by other AD regimens. Among 2751 PTD subjects, 576 (20.94%, 95% CI: 19.46, 22...
June 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28266722/development-and-validation-of-a-hplc-uv-method-for-the-simultaneous-determination-of-the-antipsychotics-clozapine-olanzapine-and-quetiapine-several-beta-blockers-and-their-metabolites
#19
Margarete Silva Gracia, Alexandra Köppl, Sandra Unholzer, Ekkehard Haen
A simple, accurate and selective column-switching high performance liquid chromatography (HPLC) method was developed and validated for simultaneous quantification of six beta-blockers (metoprolol MET, timolol TIM, bisoprolol BIS, propranolol PRO, carvedilol CAR and nebivolol NEB), three of their metabolites (α-hydroxy metoprolol α-HMET, N-desisopropyl propranolol DIPRO and 4'-hydroxy carvedilol 4-HCAR), three antipsychotics (olanzapine OLA, clozapine CLO and quetiapine QUE) and three of their metabolites (N-desmethyl olanzapine DMOLA, N-desmethyl clozapine DMCLO and N-desalkyl quetiapine DAQUE) in human serum...
March 7, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28262147/kerato-lenticular-ocular-deposits-and-visual-impairment-with-prolonged-chlorpromazine-use-a-case-series
#20
Guru S Gowda, Aditya Hegde, Vandita Shanbhag, Janardhanan C Narayanaswamy, T S Jaisoorya
Chlorpromazine is a low potency "typical" antipsychotic agent used to treat schizophrenia. It continues to be prescribed frequently in India owing to its lower cost. There have been previous reports of ocular adverse effects with prolonged use of chlorpromazine. We report three patients who developed corneal and lenticular opacities secondary to prolonged chlorpromazine use leading to visual impairment. Early detection of ocular deposits and switching over to risperidone from chlorpromazine helped in the reversal of chlorpromazine- induced ocular side effects in one of them...
February 2017: Asian Journal of Psychiatry
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"